Autoimmune Cerebellar Ataxia Panel Test is a specialized diagnostic examination designed to identify the presence of specific antibodies that may contribute to autoimmune cerebellar ataxia, a condition where the immune system mistakenly attacks the cerebellum, part of the brain that controls coordination and balance. This comprehensive panel aims to facilitate the accurate diagnosis of autoimmune-related cerebellar ataxia, distinguishing it from other types of ataxia caused by genetic factors, toxins, or other diseases. Conducted at DNA Labs UAE, a facility known for its advanced diagnostic technologies and expertise in genetic and autoimmune disorders, the test costs 11,790 AED. By pinpointing the exact antibodies causing the immune response, healthcare providers can tailor treatment plans more effectively, offering hope for improved management of symptoms and quality of life for affected individuals.
The Oncomine Focus Panel Test, offered at DNA Labs UAE for a cost of 9000 AED, is a state-of-the-art genetic test designed to identify specific mutations in cancer cells. This targeted sequencing panel is utilized to analyze a select set of genes that are known to be involved in various types of cancers. By pinpointing these genetic alterations, the test aids oncologists in developing personalized treatment plans for patients, potentially improving outcomes and minimizing unnecessary treatments. DNA Labs UAE, equipped with advanced genomic technologies, ensures precise and reliable results, making the Oncomine Focus Panel Test a valuable tool in the field of precision oncology.
Pre-Implantation Genetic Diagnosis (PGD) for single gene disorders with a known mutation is a cutting-edge genetic testing procedure designed to identify genetic abnormalities in embryos before implantation. This test is particularly vital for couples who are at risk of passing on genetic disorders to their offspring. By pinpointing the specific mutation in an embryo, PGD allows for the selection of healthy embryos for implantation, significantly reducing the risk of having a child affected by the genetic condition in question.
At DNA Labs UAE, this specialized test is offered at a cost of 9000 AED. The process involves collecting a small number of cells from embryos created through in vitro fertilization (IVF) and analyzing them for the presence of the known genetic mutation. This baseline test is crucial for couples who are carriers of or have a family history of genetic disorders, offering them a path to having biologically related children with significantly lowered genetic risks. DNA Labs UAE utilizes state-of-the-art technology and expertise to ensure accurate, reliable results, providing invaluable peace of mind and support to prospective parents navigating the complexities of genetic disorders.
The Comprehensive Tumor Panel 270 Genes and PD-L1 Test is a cutting-edge diagnostic tool available at DNA Labs UAE, designed to provide a detailed genetic profile of tumors. Priced at 9000 AED, this test analyzes 270 genes associated with various cancers, offering insights into the genetic alterations and mutations that could be driving the growth and spread of cancer cells. Additionally, it includes an assessment for PD-L1, a protein that plays a critical role in the body's immune response to cancer. By evaluating the presence and expression level of PD-L1, this test can help in identifying patients who are likely to benefit from immunotherapy treatments. This comprehensive approach not only aids in the accurate diagnosis and understanding of an individual’s cancer but also guides personalized treatment strategies, enhancing the potential for successful outcomes.
The Oncopro PD-L1 Circulating Tumor Cells Test is a cutting-edge diagnostic tool available at DNA Labs UAE, designed to detect and quantify circulating tumor cells (CTCs) that express the PD-L1 protein in a patient's bloodstream. This test is particularly valuable for patients with various types of cancer, as the presence and level of PD-L1 expression on CTCs can provide critical information regarding the tumor's biology, potential aggressiveness, and possible response to certain immunotherapy treatments.
By isolating and analyzing CTCs, the Oncopro PD-L1 test offers a non-invasive alternative to traditional biopsy methods, allowing for the monitoring of cancer progression and response to treatment over time without the need for surgical procedures. This can be especially beneficial for patients with tumors that are difficult to access or for those in whom multiple biopsies are risky or not feasible.
The test cost is set at 9880 AED, reflecting the sophisticated technology and expertise required to accurately identify and quantify PD-L1 expressing CTCs. Conducted at DNA Labs UAE, a facility known for its advanced diagnostic services and commitment to precision medicine, the Oncopro PD-L1 Circulating Tumor Cells Test represents a significant advancement in the personalized treatment of cancer, offering hope for more targeted and effective therapies based on the unique characteristics of each patient's disease.
The NGS Homologous Recombinant Deficiency (HRD) Panel Test is a cutting-edge genetic testing procedure conducted at DNA Labs UAE, designed to assess the efficiency of DNA repair mechanisms in cells, particularly focusing on the homologous recombination repair (HRR) pathway. This test is pivotal in the realm of personalized medicine, especially for patients with cancer, as defects in the HRR pathway are associated with increased sensitivity to certain chemotherapeutic agents and PARP inhibitors.
Utilizing Next-Generation Sequencing (NGS) technology, this panel test comprehensively scans for mutations in genes involved in the HRR pathway, such as BRCA1, BRCA2, and others, which are crucial for accurate DNA repair. Identifying deficiencies in homologous recombination can help predict the response to specific cancer therapies, enabling healthcare providers to tailor treatment plans to the genetic profile of the patient's tumor, thereby enhancing treatment efficacy and potentially improving patient outcomes.
The test cost is set at 10530 AED, reflecting the sophisticated technology and expertise required to perform this advanced genetic analysis. Conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services, the NGS HRD Panel Test represents a significant advancement in the field of oncology and personalized medicine, offering hope for more effective and customized cancer treatment strategies.
The Oncomine Tumor Mutation Burden (TMB) Test is a cutting-edge genomic profiling tool designed to evaluate the mutation burden within a tumor's DNA. This comprehensive assessment is performed at DNA Labs UAE, a leading facility in genomic and molecular diagnostics. The test specifically quantifies the number of mutations per megabase of DNA in a tumor sample, providing crucial insights that can guide personalized cancer treatment strategies.
With a cost of 8400 AED, the Oncomine TMB Test stands as a valuable investment for patients and healthcare providers seeking to optimize cancer therapy. By identifying the tumor mutation burden, this test can help predict response to certain immunotherapies, making it a key component in the management of various cancer types. The results from the Oncomine TMB Test enable clinicians to tailor treatment plans more effectively, potentially improving patient outcomes in the rapidly evolving field of oncology.
The PD-L1 genetic test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to evaluate the expression of the Programmed Death-Ligand 1 (PD-L1) gene. PD-L1 is a protein that plays a crucial role in suppressing the immune system, particularly in the context of cancer, by interacting with the PD-1 receptor on T cells. This interaction helps cancer cells evade immune detection and destruction. The test is particularly valuable for patients with certain types of cancer, as it helps oncologists determine the likelihood of response to immunotherapy treatments targeting the PD-1/PD-L1 pathway.
The process involves analyzing a sample of the patient's tumor tissue to measure the level of PD-L1 expression. High levels of PD-L1 may indicate that the patient is more likely to benefit from PD-1/PD-L1 inhibitor therapies, which can block this interaction and enhance the immune system's ability to fight cancer.
At DNA Labs UAE, the PD-L1 genetic test is conducted with precision and care, ensuring reliable results for patients and their healthcare providers. The cost of the test is 8400 AED, reflecting the sophisticated technology and expertise required to perform this advanced genetic analysis. By offering this test, DNA Labs UAE plays a crucial role in the personalized treatment of cancer, enabling more targeted and effective therapies based on the genetic profile of each patient's tumor.
The Oncopro Comprehensive Cancer Panel 161 Genes Test, available at DNA Labs UAE, is a sophisticated diagnostic tool designed to offer a detailed genetic analysis relevant to a wide range of cancers. Priced at 8400 AED, this test screens for mutations in 161 genes associated with increased cancer risk, aiding in the early detection and personalized treatment planning for patients. By analyzing an individual's genetic makeup, healthcare professionals can identify specific genetic mutations that may contribute to the development and progression of cancer. This information is crucial for crafting targeted therapy plans, making risk assessments, and implementing preventive measures for individuals at heightened risk. Conducted in the advanced facilities of DNA Labs UAE, this comprehensive panel is a pivotal step towards personalized medicine in oncology, offering hope for more effective and tailored cancer care strategies.
The HLA Single Antigen Bead (SAB) assay for Class I and II IgG antibodies, commonly referred to as the DSA-SAB Class I and II Test, is a sophisticated diagnostic tool used in immunology and transplant medicine. This assay is designed to detect and identify specific donor-specific antibodies (DSAs) against HLA Class I and Class II antigens in patients who have received or are planning to receive organ transplants. The presence of these antibodies can significantly impact the success of transplantation, as they are associated with acute and chronic rejection of the transplanted organ.
The test utilizes a flow cytometry-based method, where beads coated with purified HLA antigens are mixed with a sample of the patient's serum. If the serum contains antibodies against the HLA antigens present on the beads, they will bind to the beads. The bound antibodies are then detected using a fluorescently labeled anti-human IgG antibody, and the fluorescence intensity is measured. This method allows for the precise identification of the HLA antibodies present, enabling clinicians to make informed decisions regarding transplant compatibility and the management of immunosuppressive therapies.
The DSA-SAB Class I and II Test is available at DNA Labs UAE, a leading diagnostic and research facility in the United Arab Emirates. The test is priced at 9830 AED, reflecting the advanced technology and expertise required to perform this detailed analysis. This assay plays a critical role in transplant immunology, helping to increase the success rates of organ transplants by guiding the selection of compatible donors and tailoring immunosuppressive treatment to minimize the risk of rejection.
